HCC Clinical Trials

33 recruiting

Frequently Asked Questions

Common questions about HCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 162 trials

Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting
Phase 2

Phase 2 Study of WGI-0301 for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.60 enrolled4 locationsNCT06309485
Recruiting
Phase 2

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Hepatocellular Carcinoma (HCC)
Akeso100 enrolled1 locationNCT07052253
Recruiting
Phase 1

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Not Applicable

Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)
University of Aarhus617 enrolled6 locationsNCT07469319
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Not Applicable

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Intrahepatic CholangiocarcinomaHepato Cellular Carcinoma (HCC)
University Hospital, Angers206 enrolled14 locationsNCT06990659
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled45 locationsNCT07291076
Recruiting

Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma
Chinese University of Hong Kong15 enrolled1 locationNCT06885879
Recruiting
Not Applicable

SBRT in HCC With Oligoprogression on First-line Immunotherapy

HCC
Chinese University of Hong Kong30 enrolled1 locationNCT06434480
Recruiting
Phase 2Phase 3

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
University Hospital, Basel, Switzerland152 enrolled3 locationsNCT07302919
Recruiting

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

Targeted TherapyImmunotherapyHepatocellular Carcinoma (HCC)+2 more
Nanfang Hospital, Southern Medical University90 enrolled1 locationNCT07436845
Recruiting

Same-day Radioembolization for Large HCC

Hepatocellular Carcinoma (HCC)
Seoul National University Hospital138 enrolled4 locationsNCT06944483
Recruiting
Phase 2

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Hepatocellular Carcinoma Non-resectableHCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest55 enrolled12 locationsNCT04522544
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 2

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Tongji Hospital94 enrolled1 locationNCT07413354
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+17 more
Parabilis Medicines, Inc.575 enrolled23 locationsNCT05919264
Recruiting
Not Applicable

Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma (HCC)
Bangladesh Medical University40 enrolled1 locationNCT07408804
Recruiting
Phase 2

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Liver CancerLiver MetastasesIntrahepatic Cholangiocarcinoma+1 more
Stanford University62 enrolled1 locationNCT07223307